Alglucosidase Alpha

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Myozyme; Belgium: Myozyme; Bulgaria: Myozyme; Cyprus: Myozyme; Czech Republic: Myozyme; Denmark: Myozyme; Estonia: Myozyme; Finland: Myozyme; France: Myozyme; Germany: Myozyme; Greece: Myozyme; Hungary: Myozyme; Ireland: Myozyme; Italy: Myozyme; Latvia: Myozyme; Lithuania: Myozyme; Luxembourg: Myozyme; Malta: Myozyme; Netherlands: Myozyme; Poland: Myozyme; Portugal: Myozyme; Romania: Myozyme; Slovakia: Myozyme; Slovenia: Myozyme; Spain: Myozyme; Sweden: Myozyme; UK: Myozyme.

North America

USA: Lumizyme, Myozyme.

Asia

Japan: Myozyme.

Drug combinations

Chemistry

Alglucosidase Alpha: C~4758~H~7262~N~1274~O~1369~S~35~. Mw: 105338. (1) Glucosidase, prepro-α-[199-arginine,223-histidine] (human); (2) [199-Arginine,223-histidine]prepro-α-glucosidase (human). CAS-420794-05-0 (2004).

Pharmacologic Category

Enzymes. (ATC-Code: A16AB07).

Mechanism of action

Recombinant form of the enzyme acid α-glucosidase which binds to mannose-6-phosphate receptors on the cell surface, becomes internalized and transported to lysosomes, resulting in increased enzymatic activity and glycogen cleavage.

Therapeutic use

Replacement therapy for Pompe disease (infantile onset).

Pregnancy and lactiation implications

Unlabeled use

Contraindications

Hypersensitivity to alglucosidase alpha or any component of the formulation.

Warnings and precautions

Severe hypersensitivity reactions (anaphylactic reactions and anaphylactic shock) might occur. Patients with cardiovascular and respiratory diseases are at increased risk of infusion-related reactions (arrhythmias, cardiorespiratory failure). Risk of infusion-related cardiorespiratory failure in Pompe disease (possibly due to fluid overload).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart